Modified DNase and uses thereof
Modified DNase I protein in which one or more amino acids of a DNase I protein are modified non-cellularly, are provided. The modified DNase I protein exhibits a DNA hydrolytic activity in the presence of actin and an improved DNA hydrolytic activity compared to a homologous non-modified DNase I protein. Processes of preparing the modified DNase I protein and uses thereof in, for example, reducing a DNA content in sputum and/or in treating a disease or condition associated with excess extracellular DNA in a fluid, secretion or tissue of a subject, are also provided.
1. A modified DNase I protein comprising an amino acid sequence of a DNase I protein in which at least five carboxylic acid groups in said DNase I protein are each replaced by an amide group of the formula:
—C(═O)—NR′R″
wherein each of R′ and R″ is independently selected from the group consisting of hydrogen, and a saturated or unsaturated, substituted or non-substituted hydrocarbon moiety, optionally interrupted by one or more heteroatoms, said hydrocarbon moiety comprising from 1 to 20 carbon atoms, and wherein at least one of R′ and R″ is said saturated or unsaturated, substituted or non-substituted hydrocarbon moiety,
the modified DNase I protein being characterized by a catalytic efficiency with respect to DNA hydrolytic activity in the absence of actin which is greater than a catalytic efficiency of a non-modified DNase I protein with respect to DNA hydrolytic activity in the absence of actin, wherein the modified DNase I protein differs from said non-modified DNase I protein only in said at least five carboxylic acid groups being replaced by said amide group.
2. The modified DNase I protein of claim 1 , being characterized by at least one property selected from the group consisting of:
a) a DNA hydrolytic activity in the presence of 5 μg/ml human non-muscle actin which is at least 50% of a DNA hydrolytic activity of the modified DNase I protein in the absence of human non-muscle actin, at a modified DNase I concentration of 45 ng/ml;
b) a DNA hydrolytic activity in the presence of 50 μg/ml human non-muscle actin which is at least 20% of a DNA hydrolytic activity of the modified DNase I protein in the absence of human non-muscle actin, at a DNase I concentration of 45 ng/ml;
c) a DNA hydrolytic activity in the presence of 5 μg/ml human non-muscle actin which is at least 150% of a DNA hydrolytic activity of said non-modified DNase I protein in the presence of 5 μg/ml human non-muscle actin, at a DNase I concentration of 45 ng/ml;
d) a DNA hydrolytic activity in the presence of 50 μg/ml human non-muscle actin which is at least 150% of a DNA hydrolytic activity of said non-modified DNase I protein in the presence of 50 μg/ml human non-muscle actin, at a DNase I concentration of 45 ng/ml; and
e) an IC 50 with respect to DNA hydrolytic activity in the presence of human non-muscle actin which is at least twice an IC 50 of said non-modified DNase I protein with respect to DNA hydrolytic activity in the presence of human non-muscle actin.
3. The modified DNase I protein of claim 1 , wherein said amide group has the general formula:
—C(═O)—NH—R′
wherein R′ is selected from the group consisting of alkyl, alkenyl and alkynyl, each being non-substituted or substituted with one or more substituents selected from the group consisting of hydroxy and amino.
4. The modified DNase I protein of claim 3 , wherein R′ comprises from 1 to 10 carbon atoms.
5. The modified DNase I protein of claim 3 , wherein R′ is 2-aminoethyl.
6. The modified DNase I protein of claim 1 , wherein said at least five carboxylic acid groups are each individually selected from the group consisting of a carboxylic group within a side chain of an amino acid residue and a C-terminal carboxylic acid group.
7. The modified DNase I protein of claim 1 , wherein at least seven of said carboxylic acid groups of the DNase I protein are replaced by said amide group.
8. The modified DNase I protein of claim 1 , being characterized by a Michaelis constant with respect to DNA hydrolytic activity which is lower than a Michaelis constant of said non-modified DNase I protein with respect to DNA hydrolytic activity.
9. The modified DNase I protein of claim 1 , being characterized by a Michaelis constant with respect to DNA hydrolytic activity which is no more than 20 μg/ml DNA.
10. The modified DNase I protein of claim 1 , being characterized by a specific activity with respect to DNA hydrolytic activity which is at least 70% of a specific activity of said non-modified DNase I protein with respect to DNA hydrolytic activity.
11. The modified DNase I protein of claim 1 , wherein said catalytic efficiency of the modified DNase I protein is at least 150% of said catalytic efficiency of said non-modified DNase I protein.
12. The modified DNase I protein of claim 1 , wherein less than 10 weight percent of the modified DNase I is in a multimeric form.
13. The modified DNase I protein of claim 1 , wherein said DNase I protein is a plant-recombinant protein.
14. The modified DNase I protein of claim 1 , wherein said DNase I protein has at least 80% homology to a human DNase I protein having the amino acid sequence set forth in SEQ ID NO: 1.
15. A process for preparing the modified DNase I protein of claim 1 , the process comprising reacting said DNase I protein with an amine-containing compound of the formula:
HNR′R″
in the presence of a coupling agent,
wherein each of R′ and R″ is a saturated or unsaturated, substituted or non-substituted hydrocarbon moiety, optionally interrupted by one or more heteroatoms independently selected from the group consisting of hydrogen, and a substituted or non-substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroalicyclic and heteroaryl.
16. A pharmaceutical composition comprising, as an active ingredient, the modified DNase I protein of claim 1 and a pharmaceutically acceptable carrier.
17. The pharmaceutical composition of claim 16 , further comprising a calcium salt.
18. A method of reducing the viscosity of sputum, the method comprising contacting the sputum with the modified DNase I protein of claim 1 , thereby reducing the viscosity of sputum.
19. A method of reducing a DNA content in sputum, the method comprising contacting the sputum with the modified DNase I protein of claim 1 , thereby reducing a DNA content in sputum.
20. A method of treating a disease or condition associated with excess extracellular DNA in a fluid, secretion or tissue of a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the modified DNase I protein of claim 1 , thereby treating the disease or condition.
21. The method of claim 20 , wherein said disease or condition is a pulmonary disease or condition.
22. A method of treating cystic fibrosis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the modified DNase I protein of claim 1 , thereby treating cystic fibrosis.
23. A method of treating a disease or condition selected from the group consisting of bronchitis, non-cystic fibrosis bronchiectasis, chronic obstructive pulmonary disease (COPD), lupus erythematosus, lupus nephritis, Cockayne syndrome, Angelman syndrome, male infertility, metastatic cancer, a viral, bacterial, fungal or protozoan infection sepsis, myocardial infarction, atherosclerosis, diabetes, delayed type hypersensitivity and a uterine disorder, the method comprising administering to the subject in need thereof a therapeutically effective amount of the modified DNase I protein of claim 1 , thereby treating the disease or condition.
24. The method of claim 20 , wherein said subject is afflicted by a Pseudomonas lung infection.